leisure time -WSS

leisure time

author：comprehensive 2025-09-28 00:51:57 - browse：983

Rachel Haurwitz of Caribou Biosciences — Rachel Haurwitz, CEO of Caribou Biosciences. Elizabeth D. Herman for STAT

Caribou Biosciences said Thursday that its off-the-shelf CAR-T therapy induced durable, complete remissions in patients with advanced B-cell lymphoma that move it closer to the benchmarks set by more established, patient-specific CAR-T therapies.

In an update to an early-stage study, 44% of the 16 patients treated with Caribou’s on-demand therapy, called CB-010, achieved a complete remission lasting a minimum of six months — a key threshold of durability.

The CB-010 result is still preliminary, but it begins to compare favorably to currently approved CAR-T therapies, which must be custom made for each patient and have shown durable remission rates in the range of 36-40%, said Caribou CEO Rachel Haurwitz.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Drug companies' payments and gifts affect physicians' prescribing

knowledge

WSS

FogPharma raises $145 million in rare Series E round

People with mental disorders often marry others with same

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Hundreds died while taking an arthritis drug, but nobody alerted patients

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Drug companies' payments and gifts affect physicians' prescribing

Wikipedia

leisure time

hotspot

Cancer drug shortages should be causing more outrage

International team creates first chimeric human

BioMarin wins approval for gene therapy to treat hemophilia A

How to address the problem of discarded donor organs

Psychedelics group wrestles with new pharma identity

Overprescribed: High cost isn't America's only drug problem

Heart attack and stroke risk calculators need revising

International team creates first chimeric human

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Medical device lobby: We're tired of waiting on Medicare coverage

focus

Clinical trials giant ICON acquires HumanFirst

Scientific mystery highlights the blind spots in genomics databases

Medical device lobby: We're tired of waiting on Medicare coverage

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

Overprescribed: High cost isn't America's only drug problem

Obesity now affects over 1 billion people worldwide, study finds

explore

knowledge

explore

Wikipedia